Metformin impacts the prognosis of cancer patients with type 2 diabetes

Mihaela Aldea, Lucian Craciun, Carmen Crivii

Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

Résumé

A long term complication of diabetes is the increased susceptibility to develop various malignancies and also to negatively impact the progression of cancer. However, metformin, widely used in the treatment of type II diabetes, seems to impact the outcome of several types of cancer, in terms of overall survival, disease-free survival or rates of recurrences. Metformin might impact cancer through various mechanisms, including reduced insulin and insulin-like growth factor-mediated signaling as well as modulation of inflammation and adipokine activity. This review presents the clinical studies that deal with the prognostic impact of metformin on cancer and discuss the possible reasons for why certain types of cancer are affected by anti-diabetic therapy. In addition, it tries to integrate the preclinical and clinical evidence into guidelines for future prospective clinical studies.

langue originaleAnglais
Pages (de - à)111-120
Nombre de pages10
journalRomanian Journal of Diabetes, Nutrition and Metabolic Diseases
Volume21
Numéro de publication2
Les DOIs
étatPublié - 1 janv. 2014
Modification externeOui

Contient cette citation